Implications of the Parenteral Opioid Shortage for Prescription Patterns and Pain Control Among Hospitalized Patients With Cancer Referred to Palliative Care.


Journal

JAMA oncology
ISSN: 2374-2445
Titre abrégé: JAMA Oncol
Pays: United States
ID NLM: 101652861

Informations de publication

Date de publication:
01 Jun 2019
Historique:
pubmed: 22 3 2019
medline: 11 2 2020
entrez: 22 3 2019
Statut: ppublish

Résumé

The recent parenteral opioid shortage (POS) has potential implications for cancer-related pain management in hospitalized patients. This study compared changes in opioid prescriptions and clinically improved pain (CIP) among patients treated by an inpatient palliative care (PC) team before and after our institution first reported the POS. A cohort study of 386 eligible patients with cancer treated at a comprehensive cancer center 1 month before and after the announcement of the POS. We reviewed data from electronic health records, including patient demographics, opioid type, route of administration, and dose. Board-certified palliative care specialists assessed CIP at follow-up day 1. The announcement of the POS by the institution's pharmacy and therapeutics committee on February 8, 2018. The primary outcome was to measure the change in opioid prescription patterns of physicians, and the secondary outcome was to measure the proportion of patients who achieved CIP before and after announcement of the POS. Of 386 eligible patients, 196 were men (51%), 270 were white (70%), and the median age was 58 years (interquartile range, 46-67 years). Parenteral opioids were prescribed less frequently by the referring oncology teams after the POS (56 of 314 [18%]) vs before the POS (109 of 311 [35%]) (P < .001). The PC team also prescribed fewer parenteral opioids after the POS (96 of 336 [29%]) vs before the POS (159 of 338 [47%]) (P < .001). After the POS (vs before the POS), significantly fewer patients achieved CIP on follow-up day 1 (119 [62%] vs 144 [75%] of 193; P = .01). Multivariate analysis showed that before the POS, patients had an 89% higher chance of achieving CIP on follow-up day 1 (odds ratio, 1.89; 95% CI, 1.22-2.94; P = .005). There was a significant change in opioid prescription patterns associated with the POS. Furthermore, after the POS, fewer patients achieved CIP. These factors have potential implications for patient satisfaction and hospital length of stay.

Identifiants

pubmed: 30896771
pii: 2728811
doi: 10.1001/jamaoncol.2019.0062
pmc: PMC6567824
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

841-846

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Références

J Pain Symptom Manage. 2016 Jun;51(6):1070-1090.e9
pubmed: 27112310
J Pain Symptom Manage. 2010 Sep;40(3):327-41
pubmed: 20580201
Lancet Oncol. 2012 Feb;13(2):e58-68
pubmed: 22300860
J Opioid Manag. 2018 Mar/Apr;14(2):81-82
pubmed: 29733093
Am J Psychiatry. 1974 Oct;131(10):1121-3
pubmed: 4416585
Thorax. 2002 Nov;57(11):939-44
pubmed: 12403875
J Clin Oncol. 2007 May 1;25(13):1792-801
pubmed: 17470871
J Clin Oncol. 2016 Feb 10;34(5):436-42
pubmed: 26644526
Pain Physician. 2013 Jul-Aug;16(4):379-89
pubmed: 23877454
N Engl J Med. 2018 Aug 16;379(7):601-603
pubmed: 30020849
Clin Pharmacol Ther. 2013 Feb;93(2):170-6
pubmed: 23337525
Pain Physician. 2012 Jul;15(3 Suppl):ES39-58
pubmed: 22786461
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Am J Hosp Palliat Care. 2018 Aug;35(8):1118-1122
pubmed: 29649890
Cancer Surv. 1988;7(1):195-208
pubmed: 2454740
J Palliat Care. 1991 Summer;7(2):6-9
pubmed: 1714502
Eur J Intern Med. 2016 Oct;34:e39-e40
pubmed: 27449119
J Pain Symptom Manage. 1990 Dec;5(6):341-4
pubmed: 2269800
Crit Rev Oncol Hematol. 2011 Dec;80(3):460-5
pubmed: 21215653
Lancet Oncol. 2010 May;11(5):484-9
pubmed: 20434717
Am Soc Clin Oncol Educ Book. 2017;37:705-713
pubmed: 28561731
J Clin Oncol. 2014 Jun 1;32(16):1727-33
pubmed: 24799490

Auteurs

Ali Haider (A)

Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.

Yu Qian (Y)

Department of Thoracic Cancer, Hubei Cancer Hospital, Wuhan, China.

Zhanni Lu (Z)

Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.

Syed Naqvi (S)

Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.

Amy Zhuang (A)

Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.

Akhila Reddy (A)

Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.

Shalini Dalal (S)

Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.

Joseph Arthur (J)

Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.

Kimberson Tanco (K)

Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.

Rony Dev (R)

Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.

Janet Williams (J)

Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.

Jimin Wu (J)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston.

Diane Liu (D)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston.

Eduardo Bruera (E)

Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH